Biohaven Pharmaceutical Holding Company Ltd (NY: BHVN )
73.65 USD +1.32 (+1.82%) Official Closing Price Updated: 7:00 PM EDT, Apr 20, 2021 Add to My Watchlist
Press releases about Biohaven Pharmaceutical Holding Company Ltd
Biohaven Highlights Neuroscience Advancements with 22 Presentations at the 2021 American Academy of Neurology (AAN) Virtual Annual Meeting
April 13, 2021
- Pivotal trial of rimegepant for the preventive treatment of migraine spotlights reduction of 4.3 monthly migraine days during weeks 9-12 and rapid onset of preventive effects observed within the...
- NURTEC® ODT achieved preliminary net product revenue of approximately $43.8 million for the first quarter of 2021
Rick Ware Racing, Biohaven's Nurtec ODT and Nine Line Apparel Honor Fallen Service Members
April 06, 2021
Biohaven Enrolls First Patient in Phase 2/3 Trial of Oral Zavegepant, Prompting $100 Million Milestone Funding Payment from Royalty Pharma
March 29, 2021
-- Zavegepant is a high affinity, selective and structurally unique, third generation, CGRP receptor antagonist in development for both migraine and non-migraine CGRP-mediated diseases
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial–stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative,...
Biohaven Announces Proposed Public Offering Of Common Shares
March 15, 2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a marketed drug for the acute treatment of migraine and a portfolio of innovative,...
Biohaven's NURTEC® ODT Approved In United Arab Emirates For Acute Treatment Of Migraine
March 11, 2021
- NURTEC ODT obtained market authorization in the United Arab Emirates, along with the recent approval in Israel
Biohaven Announces Completion Of 50% Enrollment Ahead Of Timelines In Verdiperstat Pivotal HEALEY ALS Platform Trial At Massachusetts General Hospital
March 10, 2021
- Biohaven's verdiperstat was selected as one of the first three drug candidates to be studied in the innovative HEALEY ALS Platform Trial at MGH
- NURTEC ODT is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a fast-acting orally disintegrating tablet (ODT)
Artizan Biosciences Closes $11 Million Series A-2 Financing and Enters Option and License Agreement with Biohaven Therapeutics
March 01, 2021
Biohaven Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Developments
March 01, 2021
- NURTEC® ODT (rimegepant) net product revenues for the fourth quarter of 2020 were $35.1 million, representing a 98% increase compared to the third quarter of 2020, and $63.6 million for calendar year...
Biohaven To Report Fourth Quarter And Full Year 2020 Financial Results And Recent Business Developments On March 1, 2021
February 23, 2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN), a commercial-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates targeting neurological and...
Biohaven's BHV-1200, A Multimodal Antibody Therapy Enhancer (MATE), Demonstrates Effective Neutralization Of Multiple Strains Of COVID-19
February 22, 2021
-Biohaven's proprietary MATE™ conjugation platform has been used to generate a new class of antibody-based therapies to target COVID-19
Biohaven Provides Update On ESG Practices
February 08, 2021
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN; the "Company" or "Biohaven"), a biopharmaceutical company with a portfolio of innovative, late-stage product candidates today announced the...
Frazier Healthcare Partners announced the planned addition of Albert Cha, M.D., Ph.D. as Managing Partner on the Life Sciences team. He has over 20 years of experience investing in public and private...
- NURTEC® ODT achieved preliminary net product revenue of approximately $35 million for the fourth quarter of 2020, representing an approximately 98% increase from the prior quarter
Biohaven Signs Cody Ware as Driver for Nurtec® ODT Chevrolet for the 2021 NASCAR Cup Series Season
January 18, 2021
Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Cody Ware will pilot the Nurtec® ODT (rimegepant) #51 Chevrolet Camaro for Rick Ware Racing during the 2021 NASCAR Cup Series season. The first...
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that it has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of...
Biohaven Acquires Kleo Pharmaceuticals And Licenses Platform Technology From Yale University To Form Biohaven Labs
January 07, 2021
- Acquires full ownership of Kleo Pharmaceuticals with two novel immune modulating platforms: the Multi-targeted Antibody Therapy Enhancer (MATE™) conjugation platform and Antibody Recruiting Molecule...
Biohaven's Nurtec® ODT Partners with Rick Ware Racing for 24 Hours of Daytona Entry
January 05, 2021
Biohaven Pharmaceuticals (NYSE:BHVN) announced today that Nurtec® ODT (rimegepant) will be the primary sponsor on the #51 Ligier JS P217 entry into the LMP2 class of the 2021 24 Hours of Daytona....
Biohaven Begins Pivotal Phase 3 Trial Of Troriluzole In Obsessive-Compulsive Disorder
January 04, 2021
- Recently completed Phase 2 proof of concept study showed drug signal for troriluzole augmentation in OCD and pivotal Phase 3 trial now initiated
Biohaven's Rimegepant For Preventive Treatment Of Migraine Published In The Lancet
December 16, 2020
- Rimegepant 75 mg, already approved for the acute treatment of migraine, demonstrated efficacy and safety for the preventive treatment of migraine in this pivotal Phase 3 trial in adults
Kleo Pharmaceuticals Presents Preclinical Data on KPMW135, a Novel CD3 x CD20 Bispecific Version of Rituximab, Showing Increased Anti-Tumor Activity Compared to Rituximab, at The 62nd Annual American
December 07, 2020
Proof-of-Concept Data Demonstrates Broad Therapeutic Potential of Company’s Multi-targeted Antibody Therapy Enhancer (MATE™) Platform
Biohaven's Nurtec™ ODT Partners with the Rick Ware Racing Team in the 2021 NASCAR Cup Series
December 02, 2020
Biohaven Pharmaceuticals (NYSE:BHVN) announces today that Nurtec™ ODT (rimegepant) will be the primary partner for the No. 51 Rick Ware Racing entry during the entire 2021 NASCAR Cup Series Season,...
Sosei Heptares and Biohaven Enter Global Collaboration and License Agreement to Advance Novel Small-Molecule CGRP Antagonist Portfolio
December 01, 2020
- Biohaven acquires exclusive global rights to a portfolio of novel, small-molecule CGRP antagonists
Kleo Pharmaceuticals Announces Data Presentation on KPMW135, a Novel CD3 x CD20 Bispecific Molecule, and Conjugation Platform (MATE™) at The 62nd Annual Society of Hematology (ASH) Meeting
November 30, 2020
BioShin enrolls first patient into an Asia-Pacific regional multi-center phase III clinical trial of rimegepant (BHV-3000) for the acute treatment of migraine.
November 22, 2020
Value-based agreement between Prime Therapeutics and Biohaven aims to bring NURTEC™ ODT acute migraine treatment financial protection to health plans
November 16, 2020
Biohaven Pharmaceuticals And Weill Cornell Medicine Collaborate To Initiate Proof Of Concept Trial With CGRP Receptor Antagonist In Plaque Psoriasis
November 16, 2020
- Weill Cornell Medicine's Dr. Richard Granstein, M.D., Chairman of Dermatology, will collaborate with Biohaven to study a Calcitonin Gene-Related Peptide (CGRP) receptor-antagonist in plaque...
Biohaven Pharmaceuticals Inaugural Partner Of National Ataxia Foundation's Drug Development Collaborative
November 11, 2020
- National Ataxia Foundation (NAF) Drug Development Collaborative to cultivate resources that facilitate research and development of new potential treatments for Ataxia, a set of severe and...